During a recent update on cancer treatment, Prof. Dr. Hans Prenen, a digestive oncologist at the University Hospital of Antwerp, shared the latest data on various studies. These included the Phase II randomized AtezoTRIBE study, which explored the use of FOLFOXIRI plus bevacizumab and atezolizumab as a front-line treatment for unresectable metastatic colorectal cancer. Other studies discussed were the Phase 2 DESTINY-CRC02 study, which focused on trastuzumab deruxtecan for patients with HER2+ metastatic colorectal cancer, and the SCRUM-Japan GOZILA study, which looked at NeoRAS wild-type metastatic colorectal cancer. Lastly, the 7-year results of the PRODIGE 23 Phase III trial in locally advanced rectal cancer were summarized.
With the educational support of:
